swissfillon, a specialist in sterile filling of complex pharmaceuticals, is joining 31 Group-backed ten23 health, a pure-play, patient-centric and sustainable biologics drug product contract development and manufacturing organisation (CDMO). Founded in 2013 by Daniel Kehl and based in Visp Switzerland, swissfillon is a FDA and Swissmedic approved drug product-focused CDMO.
Enterprise Investment Scheme investment manager Deepbridge Capital has deployed over GBP50 million of capital into UK life sciences companies. The Deepbridge Life Sciences EIS was launched in 2017 as the first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the
Click Therapeutics (Click), a specialist in Digital Therapeutics as prescription medical treatments, has closed a USD52 million upsized Series B financing. The financing round was co-led by new investors HIG BioHealth Partners (HIG BioHealth) and Accelmed Partners II (Accelmed). Health Catalyst Capital, Revelation Partners, a top biotechnology hedge fund, and
Blue Wolf Capital Partners (Blue Wolf), a New York-based private equity firm, is to acquire CIVCO Radiotherapy, a global leader of radiotherapy patient positioning and immobilisation equipment, from Roper Technologies. With a nearly 40-year operating history and a track record of quality and reliability, CIVCO Radiotherapy serves a blue-chip customer
Mangrove Management Partners (Mangrove), a platform management company focused on optimising the delivery of vascular care, has closed a Series B equity financing round led by Wells Fargo Strategic Capital (WFSC), along with NewSpring Capital (NewSpring) and Dr Robert Bessler, the founder and CEO of Sound Physicians. Proceeds will fuel
Leucid Bio (Leucid), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, has successfully raised GBP11.5 million in a Series A financing round. The investment was led by Epidarex and new investor Vulpes Investment Management, with participation from new investors 2Invest and Future Fund of the British Business Bank,
The Riverside Company has invested in Nabenet, a provider of injury management and occupational rehabilitation services. The company is an add-on investment to Riverside’s platform, Altius Group Holdings (Altius), a leading provider of allied health services in Australia. Terms of the transaction were not disclosed. Founded in 1993 and based
North Carolina-based mammary biotechnology company BIOMILQ has successfully closeed USD21 million in Series A financing, which will enable their acceleration of bringing cell-cultured human milk to market. Leading the fundraise are Danish life science investor Novo Holdings and clean tech leader Breakthrough Energy Ventures. Additional support comes from Blue Horizon,
ICV Partners, LLC, an investment firm focused on lower middle market companies in business services, consumer goods & services, food & beverage, and healthcare, has sold Outpatient Imaging Affiliates (OIA), a scaled outpatient imaging platform that develops joint ventures with health systems to build and operate outpatient imaging centres. OIA
Fremman has acquired a majority stake in Palex, a distributor of high value-added MedTech equipment and solutions, from Ergon Capital Partners IV SCSp (Ergon) and Corpfin Capital (Corpfin), who will both remain as minority shareholders in the business. Headquartered in Barcelona (Spain) and founded in 1955 by the Knuth family,
12 November, 2026 – 5:00 pm
12 November, 2026 – 8:00 am
12 February, 2026 – 8:00 am
12 February, 2026 – 5:00 pm
